Amphastar Pharmaceuticals, Inc. $AMPH Shares Acquired by TD Asset Management Inc

TD Asset Management Inc grew its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 1.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,963,052 shares of the company’s stock after purchasing an additional 31,160 shares during the quarter. TD Asset Management Inc owned approximately 4.27% of Amphastar Pharmaceuticals worth $52,571,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. FNY Investment Advisers LLC acquired a new stake in shares of Amphastar Pharmaceuticals in the third quarter valued at approximately $26,000. Quarry LP acquired a new stake in shares of Amphastar Pharmaceuticals in the third quarter valued at approximately $32,000. Farther Finance Advisors LLC grew its position in shares of Amphastar Pharmaceuticals by 46.3% in the fourth quarter. Farther Finance Advisors LLC now owns 1,381 shares of the company’s stock valued at $37,000 after purchasing an additional 437 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Amphastar Pharmaceuticals by 37.8% in the fourth quarter. GAMMA Investing LLC now owns 1,685 shares of the company’s stock valued at $45,000 after purchasing an additional 462 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of Amphastar Pharmaceuticals by 24.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,233 shares of the company’s stock valued at $60,000 after purchasing an additional 435 shares during the last quarter. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have recently commented on AMPH. Barclays lowered their price target on shares of Amphastar Pharmaceuticals from $23.00 to $20.00 and set an “equal weight” rating on the stock in a research report on Wednesday. Piper Sandler restated a “neutral” rating and set a $21.00 target price (down from $25.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 11th. Weiss Ratings lowered shares of Amphastar Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, April 10th. Jefferies Financial Group restated a “hold” rating and set a $22.00 target price (down from $30.00) on shares of Amphastar Pharmaceuticals in a research report on Tuesday, April 21st. Finally, Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Friday, May 8th. Seven equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Amphastar Pharmaceuticals has an average rating of “Reduce” and an average price target of $24.00.

Amphastar Pharmaceuticals Stock Up 5.6%

Shares of NASDAQ AMPH opened at $19.74 on Friday. Amphastar Pharmaceuticals, Inc. has a 1 year low of $16.65 and a 1 year high of $31.26. The firm’s 50 day moving average price is $20.03 and its 200 day moving average price is $23.58. The firm has a market cap of $870.34 million, a P/E ratio of 11.89, a price-to-earnings-growth ratio of 3.68 and a beta of 0.91. The company has a debt-to-equity ratio of 0.79, a quick ratio of 2.82 and a current ratio of 3.85.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.42 earnings per share for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.28). The company had revenue of $171.17 million during the quarter, compared to analyst estimates of $173.46 million. Amphastar Pharmaceuticals had a net margin of 11.00% and a return on equity of 15.12%. As a group, sell-side analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 2.41 earnings per share for the current year.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.